申请人:——
公开号:US20030207875A1
公开(公告)日:2003-11-06
This invention provides compounds of the formula (I) and (II):
1
or the pharmaceutically acceptable esters thereof, and the pharmaceutically acceptable salts thereof: wherein R
1
is hydrogen or halo; R
2
and R
3
are independently hydrogen or C
1-6
alkyl; R
4
and R
5
are independently hydrogen or C
1-6
alkyl; R
6
is hydrogen, C
1-12
alkyl, C
1-6
alkoxy (C
1-6
)alkyl or C
1-12
alkyl substituted by up to 3 substituents selected from the groups consisting of C
3-8
cycloalkyl, aryl, heteroaryl and heterocyclic; R
7
and R
8
are hydrogen or taken together may form alkylene chain having one or two carbon atoms; R
9
is C
1-6
alkyl or C
3-8
cycloalkyl; R
10
is C
1-6
alkyl or NR
11
R
12
; L is (CR
11
R
12
)
n
or NR
11
; M is NR
11
or (CR
11
R
12
)
n
; R
11
and R
12
are independently hydrogen or C
1-6
alkyl; n is an integer from 0 to 5; and m is an integer from 0 to 2; said heterocyclic, aryl and heteroaryl are unsubstituted or are substituted by at least one substituent selected from the group consisting of halo and C
1-6
alkyl; with the proviso that when R
9
is C
1-6
alkyl, L is not NR
11
.
These compounds have 5-HT
4
receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound.
本发明提供了式(I)和(II)的化合物:1或其药学上可接受的酯和药学上可接受的盐:其中,R1是氢或卤素;R2和R3分别是氢或C1-6烷基;R4和R5分别是氢或C1-6烷基;R6是氢、C1-12烷基、C1-6烷氧基(C1-6)烷基或C1-12烷基,其被选自C3-8环烷基、芳基、杂芳基和杂环的最多3个取代基取代;R7和R8是氢或一起形成具有一个或两个碳原子的烷基链;R9是C1-6烷基或C3-8环烷基;R10是C1-6烷基或NR11R12;L是(CR11R12)或NR11;M是NR11或(CR11R12)n;R11和R12分别是氢或C1-6烷基;n是0到5的整数;m是0到2的整数;所述的杂环、芳基和杂芳基未取代或被至少一个取代基所取代,所述取代基被选自卤素和C1-6烷基;但当R9是C1-6烷基时,L不是NR11。这些化合物具有5-HT4受体结合活性,因此在哺乳动物,尤其是人类的治疗胃食管反流病、非溃疡性消化不良、肠易激综合征等方面是有用的。本发明还提供了包含上述化合物的制药组合物。